ERCC1 expression as a predictive marker of cervical cancer treated with cisplatin-based chemoradiation

Anticancer Res. 2014 Jan;34(1):401-6.

Abstract

Aim: The purpose of the present study was to evaluate the correlation between repair cross-complementing group-1 (ERCC1) status and the outcome of platin-based chemoradiation of locally advanced cervical cancer.

Patients and methods: Tumor specimens from 112 patients with locally advanced cervical cancer were evaluated for ERCC1 expression. The outcome of these patients was retrospectively assessed in correlation with ERCC1 expression.

Results: Increased expression of ERCC1 correlates with a better prognosis of cervical cancer. The 2-year overall survival was 68.6% in the group with low H-score for ERCC-1 and gradually increased in the intermediate and high H-score groups to 71.7% and 90.7%, respectively.

Conclusion: The present study did not confirm the correlation of low levels of ERCC1 expression with unfavorable outcomes of patients with locally advanced cervical cancer treated with platin-based radiochemotherapy.

Keywords: ERCC1 protein; cervical cancer; chemoradiation; cisplatin; immunohistochemistry staining.

MeSH terms

  • Adenocarcinoma / metabolism
  • Adenocarcinoma / mortality*
  • Adenocarcinoma / therapy
  • Adult
  • Aged
  • Antineoplastic Agents / therapeutic use*
  • Biomarkers, Tumor / metabolism*
  • Carcinoma, Squamous Cell / metabolism
  • Carcinoma, Squamous Cell / mortality*
  • Carcinoma, Squamous Cell / therapy
  • Chemoradiotherapy / mortality*
  • Cisplatin / therapeutic use*
  • DNA-Binding Proteins / metabolism*
  • Endonucleases / metabolism*
  • Female
  • Follow-Up Studies
  • Humans
  • Immunoenzyme Techniques
  • Middle Aged
  • Neoplasm Grading
  • Prognosis
  • Retrospective Studies
  • Survival Rate
  • Uterine Cervical Neoplasms / metabolism
  • Uterine Cervical Neoplasms / mortality*
  • Uterine Cervical Neoplasms / therapy

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor
  • DNA-Binding Proteins
  • ERCC1 protein, human
  • Endonucleases
  • Cisplatin